These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1058 related articles for article (PubMed ID: 15073259)
21. Thyroid uptake and radiation dose after (131)I-lipiodol treatment: is thyroid blocking by potassium iodide necessary? Bacher K; Brans B; Monsieurs M; De Winter F; Dierckx RA; Thierens H Eur J Nucl Med Mol Imaging; 2002 Oct; 29(10):1311-6. PubMed ID: 12271412 [TBL] [Abstract][Full Text] [Related]
22. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer. de Keizer B; Hoekstra A; Konijnenberg MW; de Vos F; Lambert B; van Rijk PP; Lips CJ; de Klerk JM J Nucl Med; 2004 Sep; 45(9):1549-54. PubMed ID: 15347723 [TBL] [Abstract][Full Text] [Related]
23. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638 [TBL] [Abstract][Full Text] [Related]
24. Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal. Taïeb D; Sebag F; Farman-Ara B; Portal T; Baumstarck-Barrau K; Fortanier C; Bourrelly M; Mancini J; De Micco C; Auquier P; Conte-Devolx B; Henry JF; Mundler O J Clin Endocrinol Metab; 2010 Jul; 95(7):3283-90. PubMed ID: 20392868 [TBL] [Abstract][Full Text] [Related]
29. Recombinant human thyrotropin before (131)I therapy in patients with nodular goitre: a meta-analysis of randomized controlled trials. Lee YY; Tam KW; Lin YM; Leu WJ; Chang JC; Hsiao CL; Hsu MT; Hsieh AT Clin Endocrinol (Oxf); 2015 Nov; 83(5):702-10. PubMed ID: 25370124 [TBL] [Abstract][Full Text] [Related]
30. Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity. Rosário PW; Borges MA; Purisch S J Nucl Med; 2008 Nov; 49(11):1776-82. PubMed ID: 18927337 [TBL] [Abstract][Full Text] [Related]
31. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. Pacini F; Molinaro E; Castagna MG; Lippi F; Ceccarelli C; Agate L; Elisei R; Pinchera A J Clin Endocrinol Metab; 2002 Sep; 87(9):4063-8. PubMed ID: 12213846 [TBL] [Abstract][Full Text] [Related]
32. 131I effective half-life and dosimetry in thyroid cancer patients. Remy H; Borget I; Leboulleux S; Guilabert N; Lavielle F; Garsi J; Bournaud C; Gupta S; Schlumberger M; Ricard M J Nucl Med; 2008 Sep; 49(9):1445-50. PubMed ID: 18703593 [TBL] [Abstract][Full Text] [Related]
33. Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitres. Silva MN; Rubió IG; Romão R; Gebrin EM; Buchpiguel C; Tomimori E; Camargo R; Cardia MS; Medeiros-Neto G Clin Endocrinol (Oxf); 2004 Mar; 60(3):300-8. PubMed ID: 15008994 [TBL] [Abstract][Full Text] [Related]
34. Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in Plyku D; Hobbs RF; Huang K; Atkins F; Garcia C; Sgouros G; Van Nostrand D J Nucl Med; 2017 Jul; 58(7):1146-1154. PubMed ID: 28104741 [TBL] [Abstract][Full Text] [Related]
35. Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma. Hänscheid H; Lassmann M; Luster M; Kloos RT; Reiners C Endocr Relat Cancer; 2009 Dec; 16(4):1283-9. PubMed ID: 19628649 [TBL] [Abstract][Full Text] [Related]
36. Follow-up on thyroidal uptake after radioiodine therapy: how robust is the peri-therapeutic dosimetry? Eschner W; Kobe C; Schicha H Z Med Phys; 2011 Dec; 21(4):258-65. PubMed ID: 21719262 [TBL] [Abstract][Full Text] [Related]
37. Thyroid Uptake and Effective Half-Life of Radioiodine in Thyroid Cancer Patients at Radioiodine Therapy and Follow-Up Whole-Body Scintigraphy Either in Hypothyroidism or Under rhTSH. Bacher R; Hohberg M; Dietlein M; Wild M; Kobe C; Drzezga A; Schmidt M J Nucl Med; 2019 May; 60(5):631-637. PubMed ID: 30315143 [TBL] [Abstract][Full Text] [Related]
38. Peripheral blood levels of thyroglobulin mRNA and serum thyroglobulin concentrations after radioiodine ablation of multinodular goiter with or without pre-treatment with recombinant human thyrotropin. Rubio IG; Silva MN; Knobel M; Romão R; Possato R; Gebrin EM; Buchpiguel C; Medeiros-Neto G J Endocrinol Invest; 2007; 30(7):535-40. PubMed ID: 17848834 [TBL] [Abstract][Full Text] [Related]
39. Evaluation of various doses of recombinant human thyrotropin in patients with multinodular goiters. Braverman L; Kloos RT; Law B; Kipnes M; Dionne M; Magner J Endocr Pract; 2008 Oct; 14(7):832-9. PubMed ID: 18996810 [TBL] [Abstract][Full Text] [Related]
40. 1-11C-methyl-4-piperidinyl-N-butyrate radiation dosimetry in humans by dynamic organ-specific evaluation. Virta JR; Tolvanen T; Någren K; Brück A; Roivainen A; Rinne JO J Nucl Med; 2008 Mar; 49(3):347-53. PubMed ID: 18287260 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]